Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFI Combined With Neoadjuvant PD-1 Inhibitors and Chemotherapy in Resectable NSCLC
NCT07843251Phase 4Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2030
01
Overview
Phase 4, open-label, single-arm trial of shenqi fuzheng injection in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Pathological Complete Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
shenqi fuzheng injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07843251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843251.